Observational to investigate the efficacy of CRESTOR 5mg in reaching LDL-C target goals in patients who are at high risk for a cardiovascular event
Study identifier:NL401345
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An observational study into the usage and efficacy of Crestor 5mg as a start dosage in achieving the LDL-C target level in both statin-naive and treated primary and secondary prevention patients with a high risk of a cardiovascular event.
Medical condition
Hypercholesteremia
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
3840
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Feb 2006
Primary Completion Date: -
Study Completion Date: 01 Jan 2009
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Netherlands Medical Director
AstraZeneca
